國藥科技(08156.HK)組合營生產口罩及醫療防護用品
國藥科技(08156.HK)公布,透過全資子公司國科防偽科技以1元人民幣(下同)代價,向崔國棟、李偉及北京信郵世通投資顧問,購入山東德吉醫療用品51%股權,並按股權比例出資255萬元,及共同經營合營公司。
公告指,山東德吉醫療用品主要從事生產及銷售一次性防護口罩、醫用防護口罩、醫用防護服、手術服、手術帽、手術鞋,計劃於3月15日前取得用於生產一次性防護口罩、醫用防護口罩及醫用防護服等的醫療器械的生產許可證及其他相關批文,口罩正式投產最低產量設定為每天不少於50萬個,醫用防護服最低產量為每天不少於5,000件。(gc/da)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.